Rare Disease Report

Is Carfilzomib Safe for AL Amyloidosis Patients?

DECEMBER 27, 2016
Brendan Weiss, MD



Brendan Weiss, MD of the University of Pennsylvania summarizes a study presented that the 2016 ASH Meeting that examined the safety and efficacy of carfilzomib to treat patients with AL amyloidosis.

Reference

Cohen AD, Landau H, Scott EC, et al. Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Presented at 58th Annual ASH Meeting & Exposition; San Diego, CA; December 3-6, 2016, Abstract 645.


Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.